Agios Pharmaceuticals (NASDAQ:AGIO) had its price objective boosted by equities research analysts at Royal Bank of Canada to $91.00 in a note issued to investors on Thursday, The Fly reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price would suggest a potential upside of 30.20% from the stock’s current price. The analysts noted that the move was a valuation call.
Other analysts also recently issued research reports about the stock. Oppenheimer set a $83.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 26th. Zacks Investment Research raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $68.00 price target on the stock in a report on Tuesday, January 9th. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 16th. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, SunTrust Banks set a $80.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 19th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $77.64.
Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded up $1.74 during midday trading on Thursday, hitting $69.89. 4,065,596 shares of the company’s stock traded hands, compared to its average volume of 503,938. Agios Pharmaceuticals has a 12 month low of $39.24 and a 12 month high of $76.02. The stock has a market capitalization of $3,407.42, a P/E ratio of -11.15 and a beta of 1.83.
In other news, insider Scott Biller sold 2,146 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $62.69, for a total value of $134,532.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David P. Schenkein sold 53,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $73.16, for a total transaction of $3,877,480.00. Following the completion of the transaction, the chief executive officer now directly owns 53,000 shares of the company’s stock, valued at approximately $3,877,480. The disclosure for this sale can be found here. In the last three months, insiders sold 80,130 shares of company stock valued at $5,561,250. Company insiders own 5.43% of the company’s stock.
Several large investors have recently bought and sold shares of AGIO. QS Investors LLC acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $144,000. State of Alaska Department of Revenue acquired a new position in Agios Pharmaceuticals during the fourth quarter worth approximately $160,000. Cubist Systematic Strategies LLC increased its position in Agios Pharmaceuticals by 1,041.0% during the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 3,123 shares during the last quarter. Bank of Montreal Can increased its position in Agios Pharmaceuticals by 74.8% during the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 1,520 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in Agios Pharmaceuticals during the third quarter worth approximately $225,000. 94.32% of the stock is owned by institutional investors and hedge funds.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
